M&A Deal Summary

Allergan Acquires Chase Pharmaceuticals

On November 22, 2016, Allergan acquired life science company Chase Pharmaceuticals from Edmond de Rothschild Private Equity for 125M USD

Acquisition Highlights
  • This is Allergan’s 21st transaction in the Life Science sector.
  • This is Allergan’s 16th largest (disclosed) transaction.
  • This is Allergan’s 21st transaction in the United States.
  • This is Allergan’s 1st transaction in District of Columbia.

M&A Deal Summary
Date 2016-11-22
Target Chase Pharmaceuticals
Sector Life Science
Buyer(s) Allergan
Sellers(s) Edmond de Rothschild Private Equity
Deal Type Add-on Acquisition
Deal Value 125M USD
Advisor(s) Cowen Group, Inc. (Financial)
Hogan Lovells (Legal)

Target

Chase Pharmaceuticals

Washington, District of Columbia, United States
Chase Pharmaceuticals Corporation, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. Chase's development program, if successful, will profoundly improve the symptomatic treatment of Alzheimer's disease.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Allergan

Parsippany, New Jersey, United States
Category Company
Founded 1956
Sector Life Science
Employees31,200
Revenue 15.8B USD (2018)
DESCRIPTION

Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.

DEAL STATS #
Overall 31 of 38
Sector (Life Science) 21 of 23
Type (Add-on Acquisition) 25 of 31
State (District of Columbia) 1 of 1
Country (United States) 21 of 27
Year (2016) 8 of 9
Size (of disclosed) 16 of 25
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-11 SERI Surgical Scaffold

Parsippany, New Jersey, United States

SERI Surgical Scaffold is a provider of silk based solutions to treat patients with soft-tissue defects.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-20 LifeCell

Branchburg, New Jersey, United States

LifeCell Corp. is a provider of applications in plastic and reconstructive surgeries and abdominal wall procedures.

Buy $2.9B

Seller(S) 1

SELLER

Edmond de Rothschild Private Equity

Investor

Category Private Equity Firm
PE ASSETS 1.2B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

DEAL STATS #
Overall 19 of 27
Sector (Life Science) 5 of 5
Type (Add-on Acquisition) 8 of 10
State (District of Columbia) 1 of 1
Country (United States) 2 of 2
Year (2016) 2 of 2
Size (of disclosed) 3 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-20 Groupe Nasse-Demeco

St Jean De La Ruelle, France

Groupe Nasse-Demeco is a provider of moving services. The company proposes three kinds of services : moving of household goods, administrative and business moves, and industrial transfers.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-04-28 European Homes

Paris, France

European Homes operates in new-build housing development, including the development of private housing estates, intermediate housing, apartment buildings and to a lesser extent, serviced plots. European Homes was founded in 1973 and is based in Paris, France.

Sell -
Mergr

Product

Company

Legal